CardiomyopathyUsefulness of Cardiac Troponins as Markers of Early Treatment Response in Cardiac Sarcoidosis
Section snippets
Methods
We considered eligible for this retrospective work all patients diagnosed with new-onset CS from December 2010 to November 2014 in 6 Finnish hospitals participating in the Myocardial Inflammatory Diseases in Finland (MIDFIN) research network.15 To be included, the patient had to (1) have newly diagnosed histologically proved CS in conformity with our earlier criteria,10, 15 (2) be treatment naive, (3) have undergone measurements of hs-cTnT or hs-cTnI at the time diagnosis and after the start of
Results
Plasma hs-cTnT, measured in 50 patients, ranged from ≤13 to 240 ng/L at presentation (median, 15 ng/L) and was abnormally elevated (>13 ng/L) in 26 patients (52%). Hs-cTnI, measured in the remaining 12 patients, ranged from 0.01 to 1.30 ng/ml (median, 0.05 ng/ml) and was elevated (>0.04 ng/ml) in 7 patients (58%). Table 1 summarizes the characteristics of the study population and compares the subgroups of normal versus elevated hs-cTnT/I. The data show that elevated hs-cTnT/I was associated
Discussion
Our findings show that circulating hs-cTnT/I are frequently, though not uniformly, elevated in newly diagnosed CS and that abnormally high values decrease rapidly in response to steroid therapy. Furthermore, elevated hs-cTnT/I concentrations associate with LV dysfunction and may predict poorer outcome although this still needs verification. These novel data suggest that hs-cTnT/I may provide a useful tool for the evaluation and care of CS.
The key stimulus to our work was the idea that
Acknowledgments
We want to thank the medical and nursing staff of the Division of Cardiology, Heart and Lung Center, Helsinki University Hospital, for help and support during this study.
References (19)
- et al.
Sarcoidosis
Lancet
(2014) - et al.
Prevention of left ventricular remodeling by long-term corticosteroid therapy in patients with cardiac sarcoidosis
Am J Cardiol
(2005) - et al.
Corticosteroid therapy for cardiac sarcoidosis: a systematic review
Can J Cardiol
(2013) - et al.
Etiology of sarcoidosis: does infection play a role?
Yale J Biol Med
(2012) - et al.
Prognosis after pacemaker implantation in cardiac sarcoidosis in Japan. Clinical evaluation of corticosteroid therapy
Sarcoidosis
(1994) - et al.
Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone
Am J Cardiol
(2001) - et al.
Efficacy of corticosteroids in sarcoidosis presenting with atrioventricular block
Sarcoidosis Vasc Diffuse Lung Dis
(2003) - et al.
Myocardial imaging with 18-F-fluoro-2 deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis
Eur J Nucl Med Mol Imaging
(2008) - et al.
Cardiac sarcoidosis: applications of imaging in diagnosis and directing treatment
Heart
(2011)
Cited by (43)
Association of longitudinal cardiac troponin trajectory with adverse events in patients with cardiac sarcoidosis
2023, International Journal of CardiologyUpdate on cardiac sarcoidosis
2023, Trends in Cardiovascular MedicineCitation Excerpt :Plasma brain natriuretic peptide was shown to predict heart failure, and troponin I was predictive of fatal VTs on multivariate analysis in a 2018 retrospective study of 172 patients with diagnosed sarcoidosis [59]. Plasma high sensitivity troponin was shown to be useful in the evaluation of disease activity and treatment response in cardiac sarcoidosis [60]. Future investigation is needed to elucidate the role of biomarkers for the detection and prognostication of cardiac sarcoidosis.
Prevalence, incidence and survival outcomes of cardiac sarcoidosis in the South Island, New Zealand
2022, International Journal of CardiologyChallenges in Cardiac and Pulmonary Sarcoidosis: JACC State-of-the-Art Review
2020, Journal of the American College of CardiologyCardiac Sarcoidosis multi-center randomized controlled trial (CHASM CS- RCT)
2020, American Heart JournalCitation Excerpt :Very recently, highly sensitive troponin T (hsTnT) and (hsTnI) assays have been developed to improve the accuracy for detecting very low levels of biomarkers. In 2015, Kandolin et al. measured highly sensitive troponin levels in 62 patients with new-onset CS.29 Thirty-three patients showed elevated concentrations at presentation; in 67% of cases, these normalized after steroid use for 4 weeks.
This work was supported by the Finnish government grant for medical research, Finnish Foundation for Cardiovascular Research, and Finnish Cultural Foundation, Helsinki, Finland.
See page 964 for disclosure information.